This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Genetic testing provides patients with a diagnosis for their illness, helps patients and family members to understand risks of developing new diseases, and can be used to support clinicaltrial advancement. However, genetic tests can be expensive and may not be covered by insurance.
When using genetic screening to identify clinicaltrial volunteers, a sponsor’s obligations for further testing and disclosure of results to patients and families are unclear, especially when the results have no impact on medical management. Guidance in this area is much needed. Read the full article!
What are the implications from these changes for clinicaltrials? How the shift towards cancer as a phenotype/genotype is being applied in clinicaltrials and how they are run •What are co-clinicaltrials and why could they hold the key to answering unmet need in cancer treatment and beyond into broader drug development?
not reached) in genomic analysis of post-progression samples from patients receiving second-line osimertinib. Importantly, a triple mutant scenario with EGFR L858R/T790M/C797S or EGFRexon19del/T790M/C797S genotype may occur in patients with T790-positive NSCLC receiving osimertinib in second or later lines. months, 95% CI 1.3,
The power of leveraging clinical data to decipher disease mechanisms and fuel drug discovery has rapidly grown in the era of genomics and personalized medicine. Genuity Science focuses on population genomics as a tool to derive novel biological insights through partnerships with industry-leading pharmaceutical and biotech companies.
In a clinicaltrial, participants demonstrated a 98% success rate after six months post implantation, with arteries widened successfully and no stent fractures observed. Delivered through a minimally invasive catheter system, the stent is positioned using X-ray imaging, then expanded via an inflatable balloon.
However, the Resilience Project’s scientists had used genomic data originally collected for other studies and, due to limitations in the original studies’ informed consent policies and a lack of infrastructure to recontact participants, none of the 13 individuals could be contacted with follow-up questions or requests.
Late-stage clinicaltrial failures are largely to blame for the lack of effective treatment options for patients with HFpEF, and poor five-year survival rates make this an area of great unmet need. There are different subtypes of heart failure that have different clinical presentations.”. Heart failure affects about 6.2
Even though clinicaltrial results were promising, adverse events and serious complications were observed. Hepatitis C treatment options, without a doubt, have improved significantly, including pan-genotypic medications that are used to treat all genotypes and subtypes. HBV DNA can be integrated into the host genome.
Melanie Blank, clinical team leader for General Medicine Branch 1 at the US Food and Drug Administration’s (FDA) Division of Clinical Evaluation and Pharmacology/Toxicology (DCEPT), the agency is seeing one or two new applications coming in every week for new gene therapies for different diseases. Reference: Chung DC, et al.
There are currently no TROP2-directed medicines approved for NSCLC, a setting where Dato-DXd has shown promising results in Phase I trials. Durvalumab ± Tremelimumab + Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIAN. Lead author. Abstract title. Presentation details. Immuno-Oncology.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content